课题基金 / 基金详情

Macaque Resources

Macaque Resources
猕猴资源
批准号:
8913419
负责人:
Louis J. Picker
金额:
$51.18万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-16 至 2016-06-30

项目摘要

项目成果

Louis J. Picker的其他基金

相似基金

相关文献

中文摘要
翻译
印度恒河猴患上一种与人类获得性免疫缺陷极为相似的疾病 当被猴免疫缺陷病毒(SIV)或嵌合猴-人感染时, 免疫缺陷病毒(SHIV),并代表了最好的动物模型的HIV感染。因为 由于猕猴和人类免疫系统的相似性,临床前疫苗的开发在很大程度上 依赖于SIV和SHIV猕猴模型。尽管它们有研究价值, 灵长类动物(NHP)是复杂的高阶物种,需要专门的基础设施和专业知识, 研究设置。NHP核心旨在巩固实验动物和细胞免疫学 艾滋病毒疫苗研究和设计(HIVRAD)项目的一部分,
英文摘要
The Indian rhesus macaque develops a disease that closely mimics human acquired immunodeficiency syndrome (AIDS) when infected by simian immunodeficiency virus (SIV) or chimeric simian-human immunodeficiency viruses (SHIV), and represents the best animal model for HIV infection. Because of the similarity of the immune systems of macaques and humans, preclinical vaccine development is heavily dependent on the SIV and SHIV macaque models. Their research value notwithstanding, nonhuman primates (NHPs) are complex, higher order species that require specialized infrastructure and expertise in a research setting. The NHP Core seeks to consolidate the experimental animal and cellular immunology portions of the HIV Vaccine Research and Design (HIVRAD) Program project,
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1: Systemic analysis of the origin and tissue effects of the 68-1 RhCMV/SIV vaccine efficacy-predictive whole blood transcriptomic signature
  • 批准号:
    10723639
  • 项目类别:
  • 资助金额:
    $40.6万
  • 财政年份:
    2023
  • 负责人:
    Louis J. Picker
  • 依托单位:
Admin Core
Immunologic and Virologic Basis of RhCMV/SIV Vaccine-Induced Replication Arrest Efficacy
Project 3: Determination of the minimal MHC-E-restricted SIV epitope targeting required for RhCMV/SIV vaccine-mediated SIV replication arrest efficacy
海外基金